Technical Analysis for EDAP - EDAP TMS S.A.
|Grade||Last Price||% Change||Price Change|
EDAP closed up 5.53 percent on Friday, January 18, 2019, on 3.96 times normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
|See historical EDAP trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||200 DMA Resistance||Bearish||0.00%|
|Jan 18||Gilligan's Island Sell Setup||Bearish Swing Setup||0.00%|
|Jan 18||Pocket Pivot||Bullish Swing Setup||0.00%|
|Jan 18||Volume Surge||Other||0.00%|
|Jan 18||Wide Bands||Range Expansion||0.00%|
|Jan 18||Gapped Up||Strength||0.00%|
|Jan 18||Overbought Stochastic||Strength||0.00%|
|Jan 18||Upper Bollinger Band Touch||Strength||0.00%|
|Jan 17||Shooting Star Candlestick||Bearish||5.53%|
|Jan 17||Lizard Bearish||Bearish Day Trade Setup||5.53%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
EDAP TMS S.A., through its subsidiaries, engages in the development, production, marketing, distribution, and maintenance of minimally invasive medical devices for the treatment of urological diseases. The company operates in two divisions, High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS). The HIFU division offers medical devices for the minimally invasive destruction of various types of localized tumors using HIFU technology. This division provides Ablatherm, a HIFU-based ultrasound guided device for the treatment of organ-confined prostate cancer. Its HIFU technology allows the surgeon to destroy a defined area of diseased tissue without damaging surrounding tissue and organs. This division also engages in the leasing of equipment, as well as the sale of disposables, spare parts, and maintenance services. It markets and sells its products through its direct marketing and sales organization, as well as through third-party distributors and agents. The UDS division provides medical devices for the minimally invasive diagnosis or treatment of urological disorders, primarily urinary stones and other clinical indications. This division manufactures lithotripters, including the Sonolith i-move and the Sonolith i-sys, for the treatment of urinary tract stones by means of ESWL technology. It is also involved in the leasing of lithotripters, as well as the sale of disposables, spare parts, and maintenance services. This division markets and sells its products through its direct sales and service platform, as well as through agents and third-party distributors. The company's customers include public and private hospitals, urology clinics, and research institutions worldwide. EDAP TMS S.A. was founded in 1979 and is based in Vaulx-en-Velin, France.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 3 bullish, 1 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more EDAP news...
|52 Week High||4.25|
|52 Week Low||1.35|
|200-Day Moving Average||2.6883|
|50-Day Moving Average||2.3467|
|20-Day Moving Average||2.1003|
|10-Day Moving Average||2.3935|
|Average True Range||0.2474|
|Chandelier Exit (Long, 3 ATRs )||2.2678|
|Chandelier Exit (Short, 3 ATRs )||2.0922|
|Upper Bollinger Band||2.8228|
|Lower Bollinger Band||1.3778|
|Percent B (%b)||0.89|
|MACD Signal Line||0.0008|
|Market Cap||77.42 Million|
|Num Shares||29 Million|
|Price-to-Earnings (P/E) Ratio||0.00|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||3.18|
|Resistance 3 (R3)||3.24||3.12||3.10|
|Resistance 2 (R2)||3.12||2.99||3.10||3.07|
|Resistance 1 (R1)||2.90||2.91||2.84||2.84||3.04|
|Support 1 (S1)||2.56||2.65||2.50||2.50||2.30|
|Support 2 (S2)||2.44||2.57||2.42||2.27|
|Support 3 (S3)||2.22||2.44||2.25|
|Support 4 (S4)||2.16|